Introduction Glucagon-like peptide 1 (GLP-1) is an incretin hormone produced and secreted by intestinal L cells in response to nutrients ingestion. GLP-1 regulates glucose metabolism mainly by stimulating postprandial insulin secretion and
Qiaoli Cui, Yijing Liao, Yaojing Jiang, Xiaohang Huang, Weihong Tao, Quanquan Zhou, Anna Shao, Ying Zhao, Jia Li, Anran Ma, Zhihong Wang, Li Zhang, Zunyuan Yang, Yinan Liang, Minglin Wu, Zhenyan Yang, Wen Zeng, and Qinghua Wang
Alessandro Pocai
insulin. Recent work on understanding the physiological function of proglucagon-derived peptides has renewed interest in glucagon-based therapeutics. One of these peptides is glucagon-like peptide-1 (GLP1), which is secreted from the L cells of the
Zhengu Liu, Violeta Stanojevic, Luke J Brindamour, and Joel F Habener
-cells to produce and secrete insulin in response to nutrients (glucose) and shortens their life span ( Grattagliano et al . 2008 , Haas & Biddinger 2009 ). In this study, we report that a nonapeptide, GLP1(28–36)amide, consisting of the C-terminal domain
Jennifer S ten Kulve, Dick J Veltman, Liselotte van Bloemendaal, Paul F C Groot, Henricus G Ruhé, Frederik Barkhof, Michaela Diamant, and Richard G Ijzerman
, Cummings 2013 ), except for glucagon-like peptide-1 (GLP1). GLP1 is a gut-derived hormone, mainly known for its glucose-lowering effects ( Kreymann et al. 1987 , Mojsov et al. 1987 ); however, numerous preclinical and clinical studies have shown that
N M Whalley, L E Pritchard, D M Smith, and A White
-cells of the intestine with PC1 catalysing the cleavage to yield glucagon-like peptide (GLP)-1 and GLP-2 ( Fig. 1 a). Evidence suggests the tissue-specific processing is due to differential expression of PC1 ( Tucker et al . 1996 ) and PC2 ( Rouille et al
Bernardo Nuche-Berenguer, Daniel Lozano, Irene Gutiérrez-Rojas, Paola Moreno, María L Mariñoso, Pedro Esbrit, and María L Villanueva-Peñacarrillo
obese subjects ( Zhao et al . 2008 , Buizert et al . 2009 ). It has been reported that the anti-diabetic peptides glucagon-like peptide 1 (GLP-1) and exendin 1–39 amide (Ex-4) show beneficial effects in reducing cholesterol and triglycerides in
Yolanda Diz-Chaves, Manuel Gil-Lozano, Laura Toba, Juan Fandiño, Hugo Ogando, Lucas C González-Matías, and Federico Mallo
and GCs impose a trend towards the development of obesity and diabetes in adulthood. Finally, we consider how the agonists of the GLP-1 receptor (GLP-1R) can interfere with these processes, modulating the activity of the HPA axis, the SNS and the
Weijuan Shao, Wenjuan Liu, Ping Liang, Zhuolun Song, Odisho Israel, Gerald J Prud’homme, Qinghua Wang, and Tianru Jin
homeostasis induced by high fat diet feeding ( Untereiner et al. 2019 ). Sitagliptin is a type 2 diabetes (T2D) therapeutic agent, which prevents degradation of native incretin hormones, including glucagon-like peptide-1 (GLP-1) and gastric inhibitory
Guillaume Mabilleau, Marie Pereira, and Chantal Chenu
needed, to reach an HbA 1C level of 7% or less. Among the most prescribed drugs, the glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently attracted attention as Glp-1r -knockout animals, and GLP-1-supplemented animals exhibited
Katrine Dahl Bjørnholm, Gro Klitgaard Povlsen, Maria Elm Ougaard, Charles Pyke, Günaj Rakipovski, Pernille Tveden-Nyborg, Jens Lykkesfeldt, and Gry Freja Skovsted
treatment with long acting GLP-1 receptor (GLP1R) agonists on renal ( Moreno et al. 2002 , Yu et al. 2003 , Bisgaard et al. 2016 , Mann et al. 2017 ) and cardiovascular disease ( Marso et al. 2016 a b ). GLP-1 is a gut derived peptide hormone
